Doxorubicin, which is an anthracycline drug, was the first FDA approved agent targeting TOP2 and is currently used for the treatment of many cancers, including ALL (Acute lymphoblastic leukaemia) and AML (acute myeloid leukaemia), Wilms’ tumour, neuroblastoma, breast, ovarian, thyroid, gastric, Hodgkin’s disease, malignant lymphoma and bronchogenic carcinoma [233,238]. The gene discussed is TOP2A; the disease is acute lymphoblastic leukemia.